Method for RGEN RNP delivery using 5′-phosphate removed RNA
AssigneeInstitute for Basic Science
InventorsJin-Soo Kim, So Jung Kim
Life of this patent
Estimating the term…
Abstract
Provided are a composition for ribonucleoprotein delivery, comprising a guide RNA free of 5′-terminal phosphates, and a method for ribonucleoprotein delivery, using the same.
Claims6
A method of decreasing expression of a gene involved in a Type I interferon response following delivery of an RNA-guided endonuclease ribonucleoprotein into a cell wherein the cell comprises the gene involved in the Type I interferon response, the method comprising
- preparing a guide RNA having a 5′ end free of both a diphosphate residue and a triphosphate residue by in vitro transcription using a prokaryote RNA polymerase followed by removing the diphosphate and the triphosphate residues of the guide RNA,
- forming the RNA-guided endonuclease ribonucleoprotein by combining a Cpf1 protein with the guide RNA having the 5′ end free of both the diphosphate residue and the triphosphate residue, administering the RNA-guided endonuclease ribonucleoprotein directly to the cell, and
- wherein the gene involved in the Type I interferon response comprises a gene selected from the group consisting of IFN-β (Interferon-beta), RIG-1 (retinoic acid-inducible gene 1), and OAS2 (2′-5′-oligoadenylate synthetase 2) genes, and the expression level of the gene involved in the type I interferon response is decreased compared to a control in which a RNA-guided endonuclease ribonucleoprotein comprising a Cpf1 protein and a guide RNA having the diphosphate residue or the triphosphate residue at the 5′ end is administered.
A method of decreasing expression of a gene involved in a Type I interferon response following delivery of an RNA-guided endonuclease ribonucleoprotein into a cell wherein the cell comprises the gene involved in the Type I interferon response, the method comprising
- preparing a guide RNA by in vitro transcription using a prokaryote RNA polymerase followed by removing the diphosphate and the triphosphate residues of the guide RNA,
- forming the RNA-guided endonuclease ribonucleoprotein by combining a Cas9 protein with the guide RNA having the 5′ end free of both the diphosphate residue and the triphosphate residue, administering the RNA-guided endonuclease ribonucleoprotein directly to the cell,
- wherein the guide RNA comprises CRISPR RNA (crRNA) and trans-activating crRNA (tracrRNA), and wherein the gene involved in the Type I interferon response is comprises a gene selected from the group consisting of IFN-β, RIG 1, and OAS2 genes, and the expression level of the gene involved in the type I interferon response is decreased compared to a control in which a RNA-guided endonuclease ribonucleoprotein comprising a Cas9 protein and a guide RNA having the diphosphate residue or the triphosphate residue at the 5′ end is administered.
Dependencies are inferred from the claim text.